Clinical trial NCT05077488: VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatment for FORehead Contouring and Marionette Lines
Official title: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatment for FORehead Contouring and Marionette Lines
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Marionette Lines Forehead Contouring
Keywords: skin depressions
Lead sponsor: Allergan
Sponsor class: INDUSTRY
Collaborators: name: Eurofins Dermscan Pharmascan
First posted: 2021-10-14
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To collect post-marketing data on Juvéderm® VOLIFT™ with Lidocaine on the following indications:

1. Marionette lines (treatment skin depressions)
2. Forehead contouring (face contouring)


Eligibility criteria: Inclusion Criteria:

1. Male or female, 18 years of age or older.
2. Signed the Independent Ethics Committee (IEC)-approved informed consent form prior to any studyrelated procedures being performed.
3. Eligible for treatment in at least one of the following treatment areas:

   1. Juvéderm VOLIFT treatment of skin depressions in the marionette lines:

      * Grade 1, 2, 3 or 4 on both sides at baseline in the Allergan Marionette Line Scale
      * Juvéderm VOLIFT is permitted in the oral commissures, at the discretion of the subject and investigator
   2. Juvéderm VOLIFT treatment for irregularities of forehead contouring as assessed by the investigator and is likely to see improvement
4. Accept the obligation not to receive any other facial procedures or treatments anywhere in the face during the study that are not related to the study.
5. Women of childbearing potential must have a negative urine pregnancy test before each injectable treatment and practice a reliable method of contraception throughout the study.
6. Ability to follow study instructions and likely to complete all required visits and assessments, as assessed by the Investigator.
7. Affiliated to a health social security system.

Exclusion Criteria:

In terms of population

1. Females who are pregnant, nursing, or planning a pregnancy.
2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
3. Subject in a social or sanitary establishment (socially or mentally vulnerable).
4. Current enrolment in an investigational drug or device study, participation in such a study within 6 weeks before enrollment, or be planning to participate in another investigation during the course of this study.
5. Is an employee (or immediate relative of an employee) of the Investigator, study staff, Allergan, or a representative of Allergan.
6. In France: subject having received 4500 euros indemnities for participation in researches involving human beings in the 12 previous months, including participation in the present study.

   In terms of associated pathology
7. Has a history of multiple or severe allergies, anaphylaxis, atopy, or allergy to lidocaine, HA products, or Streptococcal protein, or is planning to undergo desensitization therapy during the study.
8. Has an active inflammation or infection (acne, herpes,...), cancerous or precancerous lesion, or unhealed wound.
9. Subject with history of hypertrophic scarring
10. Has porphyria.
11. Has epilepsy.
12. Has impaired cardiac conduction, severely impaired hepatic function, or severe renal dysfunction.
13. History of, or currently suffering from, autoimmune disease or autoimmune deficiency or being under immunosuppressive therapy.
14. History of streptococcal disease (recurrent sore throats, acute rheumatic fever).
15. Has any uncontrolled disease.
16. Has any condition or is in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. Relating to previous or ongoing treatment
17. Has ever undergone facial plastic surgery or received permanent facial implants (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene, threads) anywhere in the face, or is planning to be implanted with any of these products during the study.
18. Has undergone semi-permanent dermal filler treatment (e.g., hyaluronic acid, calcium hydroxyapatite, poly-L-lactic acid) in the face within 12 months before enrolment or is planning to undergo such treatment during the study.
19. Has undergone mesotherapy or cosmetic resurfacing (laser, photo-modulation, intense pulsed light, radiofrequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) anywhere in the face or neck, or Botulinum toxin injections in the face within 6 months before enrolment or is planning to undergo any of these procedures during the study.
20. Has begun using any over-the-counter or prescription, oral or topical, anti-wrinkle products within 90 days before enrolment or is planning to begin using such products during the study (subjects who have been on a regimen of such products for at least 90 days are eligible for the study if they intend to continue their regimen throughout the study).
21. Is on an ongoing regimen of anti-coagulation therapy (e.g., warfarin) or non-steroidal antiinflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) or other substances known to increase coagulation time (e.g., herbal supplements with garlic or gingko) within 10 days of undergoing study device treatment (study treatment may be delayed as necessary to accommodate this 10- day washout period).
22. Is on a concurrent regimen of lidocaine or structurally related local anaesthetics (e.g., bupivacaine).
23. Is on an ongoing treatment that reduce or inhibit hepatic metabolism (cimetidine, beta-blockers, etc.).

Primary outcomes:
measure: Forehead Contouring: Proportion of subjects with a Global Aesthetic Improvement Scale (GAIS) equal to 'improved" or "much improved" as assessed by a blinded aesthetic doctor of the contouring of the forehead using a 3D image.
timeFrame: Baseline to 30 Days
measure: Marionette Lines: Proportion of subjects with a ≥1-point change in the Marionette Line scale from baseline before treatment to 30 days post treatment.
timeFrame: Baseline to 30 Days
Secondary outcomes:
measure: Forehead Contouring: Change in overall FACE-Q Satisfaction with Facial Appearance score from baseline to 30 days, 3 months, 6 months, 9 months, 12 months
timeFrame: Baseline to 30 days, 3 months, 6 months, 9 months, 12 months
measure: Marionette Lines: Proportion of subjects with a ≥1-point change in the Allergan Marionette Line scale from baseline before treatment to 3 months, 6 months, 9 months, 12 months
timeFrame: Baseline before treatment to 3 months, 6 months, 9 months, 12 months
measure: Forehead Contouring: Proportion of subjects with a GAIS equal to 'improved" or "much improved" as assessed by a blinded aesthetic doctor using a 3D image at 3 months, 6 months, 9 months and 12 months
timeFrame: 3 months, 6 months, 9 months and 12 months
measure: Marionette Lines: Change in overall FACE-Q Satisfaction with Facial Appearance score from baseline to 30 days, 3 months, 6 months, 9 months, 12 months
timeFrame: Baseline to 12 Months
measure: Forehead Contouring: Proportion of subjects with a GAIS equal to 'improved" or "much improved" as assessed by the investigator using baseline 2D photographs (live evaluation) at 30 days, 3 months, 6 months, 9 months and 12 months
timeFrame: 30 days to 12 Months
measure: Marionette Lines: Change in overall FACE-Q Appraisal of lines: marionette score from baseline to all administered timepoints
timeFrame: Baseline to 12 Months
measure: Forehead Contouring: Proportion of subjects with a GAIS equal to 'improved" or "much improved" as assessed by the subjects using baseline 2D photographs (live evaluation) at 30 days, 3 months, 6 months, 9 months and 12 months
timeFrame: 30 days, 3 months, 6 months, 9 months and 12 months
measure: Marionette Lines: Proportion of subjects with a GAIS equal to 'improved" or "much improved" as assessed by the investigator using baseline 2D photographs (live evaluation) at 30 days, 3 months, 6 months, 9 months and 12 months
timeFrame: 30 days, 3 months, 6 months, 9 months and 12 months
measure: Forehead Contouring: Volume change in the forehead using 3D imaging from baseline before treatment to 30 days, 3 months, 6 months, 9 months, 12 months
timeFrame: 30 days, 3 months, 6 months, 9 months, 12 months
measure: Marionette Lines: Volume change in the marionette lines using 3D imaging from baseline before treatment to 30 days, 3 months, 6 months, 9 months, 12 months
timeFrame: 30 days, 3 months, 6 months, 9 months, 12 months
measure: Forehead Contouring: Contour changes in the forehead using 3D imaging from baseline before treatment to 30 days, 3 months, 6 months, 9 months, 12 months
timeFrame: 30 days, 3 months, 6 months, 9 months, 12 months
measure: Marionette Lines: Proportion of subjects with a GAIS equal to 'improved" or "much improved" as assessed by the subjects using baseline 2D photographs (live evaluation) at 30 days, 3 months, 6 months, 9 months and 12 months
timeFrame: 30 days, 3 months, 6 months, 9 months and 12 months
Other outcomes:
Locations:
city: Lyon
country: France
facility: Eurofins Pharmascan /ID# 243454
Study officials:
affiliation: Allergan
name: ALLERGAN INC.
role: STUDY_DIRECTOR
References: